Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00402038 · ClinicalTrials.gov registry record · Phase 3

Study of Methylnaltrexone (MNTX) for the Relief of Constipation

A Phase 3 study, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 3
Development phase
134
Enrollment target

NCT00402038 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 134 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00402038, a Phase 3 study, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 3
Development phase
134 participants
Enrollment target

Study Summary

To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.

Interventions

  • DRUG SC Placebo
  • DRUG SC Methylnaltrexone

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2004-02
Est. Completion 2005-10
Phase Phase 3

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT00402038

The ClinicalTrials.gov registry entry for NCT00402038 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which SC Placebo is the first listed.

NCT00402038 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00402038 about?

NCT00402038 is a clinical study titled "Study of Methylnaltrexone (MNTX) for the Relief of Constipation". To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.

What is the current status of trial NCT00402038?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 134 participants. The study started on 2004-02. Estimated completion is 2005-10.

What interventions are being tested in trial NCT00402038?

The interventions under investigation include: SC Placebo (DRUG), SC Methylnaltrexone (DRUG).

Who is sponsoring clinical trial NCT00402038?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.